PDCD1 and cancer: Since HC-5404 demonstrated acceptable tolerability and safety profile in clinical settings with advanced solid tumors, it would be interesting to test whether combining HC-5404 with anti-PD-1 or VEGF receptor tyrosine kinase inhibitors could benefit cancer patients, including those with PCa, which were unresponsive or resistant to these treatments.